Advertisements

Anthralin Cream

Quick links to important sections

Anthralin Cream

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Anthralin Cream

Quick Facts

Property Description
Active Ingredient Anthralin (Dithranol)
Form Topical Cream (also available as ointment, paste)
Pharmacological Class Antipsoriatic Agent
General Purpose To normalize rapid skin cell growth
Origin Synthetic derivative (of natural Chrysarobin)

What Type of Medicine is Anthralin Cream?

Anthralin Cream is a potent topical dermatological agent specifically classified within the pharmacological class of antipsoriatics, formulated for application directly onto the skin. The medication’s primary component is the active ingredient, Anthralin, also recognized as Dithranol. Chemically, Anthralin is identified as a synthetic anthracene derivative, an older compound whose efficacy is clinically recognized for its role in long-term skin management. This treatment is notably a non-corticosteroid compound, which provides a distinct therapeutic mechanism compared to common steroid-based topicals.

The compound was originally derived from the natural substance chrysarobin, which was historically obtained from the Araroba tree. The enduring efficacy of this single-ingredient product confirms its importance as a specialized option for individuals seeking a steroid-free approach to managing chronic skin hyperproliferation.

Composition, Form, and General Purpose

Anthralin Cream is a specific dosage form—a topical cream—designed solely for application to the skin, which helps to stabilize the active ingredient for targeted dermatological delivery. The cream vehicle is generally formulated using stabilizers and emulsifiers, such as fatty alcohols, allowing for easier application and more controlled penetration compared to potentially thicker formulations. Its versatility is noted by the existence of other forms, including ointments and pastes, which offer varying levels of skin occlusion and are often chosen based on the site of application.

The overall general purpose of Anthralin is to regulate the skin's biological processes by directly inhibiting the excessive proliferation of skin cells, or keratinocytes. This is achieved through its core anti-proliferative effects. The general benefit is to reduce the rapid cell turnover and resulting excessive scaling, serving as a powerful, localized tool to normalize the affected skin's appearance and texture.

Regulatory References

  1. Anthralin DailyMed (NIH/NLM)
Advertisements

What side effects are possible with Anthralin Cream?

Possible Side Effects and Safety Information

The safety profile of Anthralin Cream (Dithranol) is characterized primarily by localized dermatological reactions that occur at the site of application. Regulatory documents consistently classify skin irritation, redness (erythema), and a burning sensation as common adverse reactions, predominantly involving the skin and subcutaneous tissues.


Official Adverse Reactions and Safety Constraints

The most notable side effects are local and generally dose-dependent, with frequency and severity often noted in official labeling.

Category Description based on Regulatory Sources
Common Local Effects Skin irritation, redness (erythema), and a burning sensation.
Clinically Significant Effect Severe contact dermatitis (allergic or irritant), which may require discontinuation of the medicine.
Inherent Safety Note The compound causes unavoidable, temporary discoloration (staining) of the skin, hair, and nails, as well as permanent staining of clothing and materials.

Safety Considerations and Restrictions

Official prescribing information includes specific constraints for its use, primarily related to the condition of the skin and the application site.

  • Time-Related Pattern: Local skin reactions are most likely to manifest at the start of treatment or when the concentration of the cream is increased, as documented in regulatory sources.
  • Application Restrictions: Use is restricted on inflamed, broken, or oozing skin, and it is contraindicated on sensitive areas such as the face, genitalia, skin folds, or during acute psoriatic flares.
  • Environmental Constraint: The product may increase sensitivity to ultraviolet light; official warnings advise the avoidance of concomitant sun exposure or UV light (phototherapy) due to the risk of phototoxicity. Contact with the eyes must also be strictly avoided.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Anthralin Cream (Dithranol) overdose is defined by the risks of accidental systemic exposure and local over-treatment, strictly following guidance from official regulatory bodies.

Overdose Circumstance Documented Manifestations and Required Action
Local Over-treatment Overuse is primarily manifested by signs of exaggerated local toxicity. This includes excessive soreness, severe skin irritation on or around the treatment area, or the spreading of psoriatic lesions. If these signs occur, regulatory guidance requires the discontinuation of use and consultation with a physician.
Accidental Ingestion Accidental oral intake of Anthralin Cream must be treated as an emergent situation due to the potential for systemic exposure. Regulatory labeling mandates that you contact a Poison Control center or emergency room at once and seek immediate medical attention.

Management and Treatment Context

Systemic toxicity is generally not observed with correct topical use, as official studies indicate low potential for absorption. Management is typically symptomatic and supportive, consistent with the official constraint that no specific antidote is known. There are no specific population-based risk factors (e.g., in pediatrics or patients with hepatic impairment) detailed in the official overdose section of the labeling.

Advertisements

Therapeutic Uses of Anthralin Cream

What Anthralin Cream Treats: Main Uses and Benefits

Management of Chronic Plaque Psoriasis

Anthralin Cream is commonly used in the management of chronic plaque psoriasis, a condition which involves persistent, stable skin lesions. The medication is applied in situations involving stable plaque psoriasis. It is commonly used to help manage the condition’s symptomatic patterns that create the patches, and supports the overall goal of managing the chronic condition.

The primary areas of use for Anthralin include stable plaque psoriasis, and its use is considered relevant for managing localized scalp psoriasis.


Easing Scaly and Thickened Lesions

This medication may provide supportive symptomatic relief from the physical burden of hyperkeratosis (skin thickening) and scaling. For symptoms related to physical discomfort, the treatment may assist in flattening the raised, red patches and assisting in easing the overall symptom load related to scale, contributing to a more improved appearance and texture during symptomatic periods.

Role in Non-Corticosteroid Regimens

Anthralin is a relevant option for individuals and clinicians seeking a non-corticosteroid treatment for localized, stable plaques. Its role as a non-corticosteroid allows it to be incorporated into long-term management plans, and may assist in providing a supportive therapeutic alternative for patients seeking a non-corticosteroid approach to symptom management.


Quick Fact: Relief for Chronic Plaque
Symptom Domain Symptoms of Thickened, Scaly Lesions
Benefit Focus Contributes to improved comfort during periods of heightened scaling
Clinical Context Long-term management and steroid-sparing regimens

Regulatory References

  1. U.S. National Library of Medicine's DailyMed overview
Advertisements

Eligibility and Restrictions for Use

Anthralin Cream is intended for specific patient populations defined by regulatory labeling. Use is contraindicated (prohibited) for any patient with a known history of hypersensitivity to the active ingredient or other components of the preparation. It must also not be used by patients experiencing acute or actively inflamed psoriatic eruptions; the medicine is only allowed for chronic, stable plaque psoriasis.

The product is prohibited for application to sensitive areas of the body, including the face, eyes, mucous membranes, and skin folds (intertriginous areas), as well as on blistered, raw, or oozing skin. Caution is also advised if other skin diseases are present, as the condition may worsen.

Age-related eligibility is restricted, as safety and effectiveness have not been established in children. For specific formulations, use may be limited to adolescents aged 12 years and older. Data for use in older adults is generally considered insufficient.

Use during pregnancy is conditional, meaning the cream should only be administered if clearly needed. For nursing mothers, caution must be exercised because it is unknown if the drug is excreted in human milk. Nursing women are specifically advised to ensure the infant's skin does not come into direct contact with any treated areas.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Anthralin Cream is a topical medication whose official regulatory profile indicates a low risk for systemic drug-drug interactions. This is primarily attributed to the medicine's limited systemic absorption and a specific finding in government documentation.

Systemic Pharmacokinetic Interactions

Official regulatory sources note that Anthralin does not inhibit liver microsomal enzyme activity. This characteristic is used to explain the low likelihood of the medicine altering the clearance or plasma concentration of other systemically administered medicines. The risk of pharmacokinetic-based conflicts with other drugs is consequently minimized.

Topical Pharmacodynamic Interactions

The principal documented interaction caution relates to the local application site. Co-administration of other topical products or medications on the same treated area may result in an additive local irritant effect. This constitutes a pharmacodynamic interaction where effects on the skin are compounded.

Other Substance Interactions

No specific interactions are formally documented in official prescribing information regarding co-administration with food, alcohol, herbal products, or supplements. Furthermore, no mandatory time separation requirements for administration relative to other medicines are specified in regulatory documents.

Advertisements

Mechanism of Action

Targeting Mitochondria and DNA

The mechanism of Anthralin (Dithranol) is a multi-targeted action that chemically inhibits the over-proliferation of skin cells and modulates local immune activity.

Anthralin's primary action involves its accumulation within the mitochondria of actively dividing skin cells (keratinocytes), where it acts as a chemical reducing agent. By disrupting the ubiquinone pool in the mitochondrial respiratory chain, the drug causes energetic stress and forces the hyperproliferative cells to undergo apoptosis (programmed cell death).

This is reinforced by redox cycling, where Anthralin's autooxidation generates reactive oxygen species (ROS) and free radicals. These molecules damage the cell’s DNA, inhibiting the synthesis of genetic material and halting mitotic activity. This dual action restricts the excessive thickening and rapid turnover rate of the tissue.

Modulating Inflammatory Pathways

Anthralin also exerts a localized anti-inflammatory mechanism by modulating the function of local T-lymphocytes. It suppresses the secretion of various pro-inflammatory mediators and disrupts key auto-inflammatory communication loops, such as the IL-36 inflammatory loop, contributing to the physiological modulation of chronic tissue inflammation.

Advertisements

Dosage and Administration Information

Official Administration Instructions

Anthralin (Dithranol) Cream is a prescription medication approved for topical use only and must be administered strictly according to the regimen defined by a healthcare provider.

Administration Detail Official Requirement
Route of Administration Topical (Dermatologic use only).
Dosing Frequency Typically applied once a day.
Application Quantity Apply a thin layer of the cream or ointment only to the affected skin lesions.
Targeting Requirement It is essential to avoid applying the product to surrounding normal skin, eyes, or mucous membranes.

Dosing and Titration Protocol

Treatment must always commence with the lowest available concentration (e.g., 0.1% strength), regardless of the site of application. The strength is then gradually titrated upwards over a period of weeks, generally at weekly intervals, until the highest tolerated strength is reached. Higher strengths (e.g., 0.5% and above) are typically intended for use under direct medical supervision.

Short Contact Therapy (SCT)

The standard method of use is Short Contact Therapy, which mandates a controlled duration of application: the cream is applied and then thoroughly removed after a specific, limited contact time, usually between 5 and 30 minutes. After the prescribed contact time, the cream must be completely removed by washing or showering. Treatment is continued until the affected skin is fully clear and the texture has normalized, which may require several weeks.

Advertisements

Recent Clinical Evidence

Evidence for Use in Chronic Plaque Psoriasis

The core evidence for anthralin is established through Randomized Controlled Trials (RCTs) and Systematic Reviews, which are widely used study designs in medical research. These studies explored measured changes when anthralin was used by adults with stable, chronic plaque-type psoriasis, including localized lesions on the scalp. In trials, anthralin was studied for symptom changes compared against a non-active cream base, examining outcomes related to physical discomfort.

Outcomes Examined in Clinical Trials

Researchers focused on measuring changes using formalized tools like the Psoriasis Area and Severity Index (PASI) and the Physician's Global Assessment (PGA), which monitor symptom intensity. Studies included comparisons of measured outcomes for groups using anthralin versus the non-active base. Research has explored various treatment schedules and formulations, and patterns in measured outcomes were observed to vary depending on the study's protocol.

Long-Term Data and Follow-Up Duration

The research that informs the regulatory understanding of anthralin is primarily focused on short-term symptom patterns, with typical follow-up durations ranging from 4 to 12 weeks. These trials were designed to examine the initial effects during the acute treatment period. As a result, there is limited information for long-term outcomes that cover maintenance treatment or durability of effects over many months or years, and long-term effects are not fully established.

Evidence in Different Patient Populations

The research base largely focuses on the populations included in the studies, mainly adults with stable plaque psoriasis. While patient samples covered a wide age range, data for certain groups remain insufficient. For instance, there are relatively few dedicated studies providing specific evidence for long-term outcomes in older adults, or for how anthralin was evaluated in pregnant populations or patients with pre-existing systemic conditions. Research does not determine whether an individual outside the studied groups will respond similarly.

Key Research Gaps and Uncertainty

Scientific reviewers have identified areas where certainty remains low. One major limitation is that follow-up durations were limited in many primary studies, making it difficult to fully assess long-term patterns. Furthermore, evidence quality varies across studies due to differences in design, formulations used, and how outcomes were reported. This variability can introduce methodological heterogeneity, and comparative evidence against other active treatments is often limited or inconsistent in reporting.

Key Studies & References

  1. ZITHRANOL-RR - anthralin cream (Official Drug Label)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Anthralin Cream (FAQ)


Q: Is Anthralin Cream ever used for conditions other than psoriasis?

A: The official documentation states that Anthralin is approved for use in psoriasis. However, official texts also note that the medicine may be used to treat other specific skin conditions, as determined by a healthcare provider.


Q: How is Anthralin Cream fundamentally different from a steroid cream?

A: Anthralin is officially classified as an antipsoriatic agent and is a non-corticosteroid compound. Its mechanism is distinct from steroids, as it chemically inhibits the excessive division of skin cells (keratinocytes) and promotes their programmed death (apoptosis).


Q: What level of skin irritation is generally considered too much when using this cream?

A: Regulatory information advises that some temporary irritation and redness are common expected effects. However, if severe soreness or too much irritation occurs, application should be stopped and a healthcare provider consulted for further guidance. This caution is primarily due to the risk of severe contact dermatitis.


Q: Can using Anthralin Cream cause skin problems in areas that are not being treated?

A: Official instructions stress the importance of applying only a thin layer strictly to the affected areas to avoid irritation on surrounding, unaffected skin. Furthermore, the regulatory text notes that petroleum jelly may be used for protection against irritation spreading to normal skin.


Q: Can I use other topical products like heavy moisturizers on the treated area?

A: Official warnings advise against using other skin care products, cosmetics, or skin products on the affected area without first consulting a healthcare provider. This is due to the potential for an additive local irritant effect, which could increase skin sensitivity.


Q: Are there known concerns with using Anthralin Cream and topical steroids together?

A: Official guidance requires that all prescription and nonprescription products be discussed with a healthcare provider before use on the same area. This is primarily to manage the risk of compounded local skin irritation when products are combined.


Q: How long does it typically take to start seeing improvements from using Anthralin Cream?

A: Clinical studies informing regulatory understanding of Anthralin typically cover a period of 4 to 12 weeks. Complete skin clearance is noted to require several weeks of continued use as defined by a healthcare provider. The time it takes to see the initial visible improvement may vary.


Q: Is there scientific evidence that Anthralin Cream can be used for hair loss (alopecia areata)?

A: The official approved indication for Anthralin is for the treatment of psoriasis. Formal evidence for use in Alopecia Areata is not a primary focus of regulatory documentation and is not provided in standard patient materials.


Q: What is known about the effects of long-term use of Anthralin Cream?

A: Official research is primarily focused on short-term symptom patterns, resulting in limited information for long-term outcomes (periods covering many months or years). Additionally, some older non-human studies have noted that the drug has been shown to cause tumors in animals, though this has not been reported in humans.


Q: Does Anthralin Cream work by slowing down skin cell growth?

A: Yes, regulatory documents describe the medicine’s general purpose as regulating the skin's biological processes. It achieves this by directly inhibiting the excessive proliferation of skin cells and halting their mitotic activity, which is commonly summarized as slowing down the growth of skin cells.


Q: Is Anthralin Cream a type of vitamin D analog or retinoid? (Clarification)

A: Anthralin (Dithranol) is officially classified as an antipsoriatic agent and a synthetic anthracene derivative. Regulatory classifications confirm it is a non-corticosteroid compound, and it is not classified as a retinoid or vitamin D analog.


Q: What is Anthralin also known as internationally?

A: The active ingredient, Anthralin, is widely recognized and officially referred to by the name Dithranol in international regulatory and medical texts.


Q: How long does the temporary discoloration of skin from Anthralin Cream usually last?

A: Official precaution statements indicate that the temporary stain on the skin and hair will typically wear off in several weeks after the use of the medicine has been discontinued. This temporary discoloration is an unavoidable, expected effect.


Q: Does Anthralin Cream stain fingernails?

A: Yes, official safety constraints confirm that the compound causes unavoidable, temporary discoloration or staining of the skin, hair, and nails. Users may wish to exercise caution during application to help minimize staining.


Q: Does Anthralin Cream discolor white or gray hair?

A: Yes, official prescribing information specifically notes that this medication may temporarily discolor gray or white hair. This temporary staining is a common, expected effect of the compound.


Q: What should be done if Anthralin Cream is accidentally swallowed?

A: Official warnings state the medicine may be harmful if swallowed, as it is only intended for topical use. If swallowing is suspected, it is advised to contact a poison control center or seek emergency medical help immediately.


Q: Is it common to feel a sensation of warmth immediately after applying Anthralin Cream?

A: Official labeling consistently lists a burning sensation, irritation, and redness as common adverse reactions that occur at the site of application. A feeling of warmth may be perceived as a mild manifestation of the common local burning sensation, which is generally dose-dependent.


Q: Can people with kidney problems use Anthralin Cream?

A: The research base largely focuses on studies in adults with stable plaque psoriasis, and data for certain pre-existing systemic conditions is considered insufficient. Some official patient-facing materials advise that a healthcare provider should be consulted if a history of kidney disease is present before using the cream.


Q: Is it safe to use other medicated shampoos alongside Anthralin Cream treatment for the scalp?

A: Official instructions for the shampoo formulation state that a non-medicated shampoo or conditioner can be used after rinsing the medicine off. All other medicated products should be discussed with a healthcare provider due to the risk of compounded local effects on the scalp.


Q: Does Anthralin interact with common over-the-counter supplements or herbal products?

A: Official regulatory documents do not formally document specific interactions with herbal products or dietary supplements. However, patients are generally advised to tell their healthcare provider about all products they are currently taking.


Q: What is the guidance regarding staining of clothes or bedding from the cream?

A: Official guidance advises users to avoid getting the medicine on clothing or bed linens due to the risk of permanent staining, which is an inherent property of the compound. Wearing a plastic cap or using protective dressings may be advised by a healthcare provider for scalp applications to protect fabrics.


Q: How can I minimize the risk of staining my bathtub or shower?

A: Official directions advise immediately rinsing any medicine off the surface of the bathtub or shower stall with water after use. It is also advised to wash the surface with a household cleanser to remove any remaining deposits and prevent permanent discoloration of the stall.


Q: Does the concentration or strength of Anthralin Cream influence the likelihood of irritation?

A: Official prescribing information indicates that the irritant potential of anthralin is directly related to the strength being used. Regulatory information indicates that treatment should commence with the lowest available concentration, which is gradually increased as tolerated.


Q: Is Anthralin Cream available over the counter in any countries?

A: In the U.S., the medicine is available only with a prescription from a doctor. Official U.S. patient-facing documents do not consistently provide the regulatory classifications for international markets.


Q: What kind of clinical research has been conducted on Anthralin Cream?

A: The core evidence for Anthralin is established through Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers utilize formalized tools to monitor symptom changes in adults with stable, chronic plaque-type psoriasis, focusing on outcomes related to physical discomfort.


Q: Can Anthralin Cream be used at the same time as light therapy (phototherapy)?

A: Official warnings advise the avoidance of concomitant sun exposure or UV light, including phototherapy. This constraint is due to the risk of phototoxicity and increased skin sensitivity.

Advertisements

How should Anthralin Cream be stored and disposed of?

How to Store and Dispose of Anthralin Cream?

Anthralin cream must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirement Official Guidance
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excessive heat.
Protection Keep the container tightly closed and protect the cream from excessive moisture and light.
Accessibility Keep this medicine out of the reach of children.

For disposal, do not discard unneeded or expired medicine in household trash or down a sink or toilet. Proper disposal should occur through a medicine take-back program or by following guidance from local waste management authorities if no take-back program is available. Follow all instructions to dispose of any remaining cream after the expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anthralin Cream found in:

A-Z Index: